Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

419 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Medullary thyroid cancer treated by capecitabine.
Labidi SI, Gravis G, Tarpin C, Brun V, Viens P. Labidi SI, et al. Anticancer Drugs. 2007 Aug;18(7):831-4. doi: 10.1097/CAD.0b013e3280adc8f3. Anticancer Drugs. 2007. PMID: 17581307
Interleukin-2 in association with increasing doses of interferon-gamma in patients with advanced cancer.
Viens P, Blaise D, Stoppa AM, Brandely M, Baume D, Olive D, Resbeut M, Delpero JR, Lopez M, Aubert C, et al. Viens P, et al. J Immunother (1991). 1992 Apr;11(3):218-24. doi: 10.1097/00002371-199204000-00009. J Immunother (1991). 1992. PMID: 1515426 Clinical Trial.
Pharmacokinetics of mitoxantrone in cancer patients treated by high-dose chemotherapy and autologous bone marrow transplantation.
Richard B, Launay-Iliadis MC, Iliadis A, Just-Landi S, Blaise D, Stoppa AM, Viens P, Gaspard MH, Maraninchi D, Cano JP, et al. Richard B, et al. Br J Cancer. 1992 Mar;65(3):399-404. doi: 10.1038/bjc.1992.81. Br J Cancer. 1992. PMID: 1558794 Free PMC article. Clinical Trial.
Phase I trial of recombinant interleukin-2 followed by recombinant tumor necrosis factor in patients with metastatic cancer.
Negrier MS, Pourreau CN, Palmer PA, Ranchere JY, Mercatello A, Viens P, Blaise D, Jasmin C, Misset JL, Franks CR, et al. Negrier MS, et al. J Immunother (1991). 1992 Feb;11(2):93-102. doi: 10.1097/00002371-199202000-00003. J Immunother (1991). 1992. PMID: 1571336
High-dose recombinant interleukin-2 and acute myeloid leukemias in relapse.
Maraninchi D, Blaise D, Viens P, Brandely M, Olive D, Lopez M, Sainty D, Marit G, Stoppa AM, Reiffers J, et al. Maraninchi D, et al. Blood. 1991 Nov 1;78(9):2182-7. Blood. 1991. PMID: 1932739
[High doses of alkylating agents and bone marrow autograft in ovarian cancer with poor prognosis: a retrospective analysis of 40 patients treated in France].
Maraninchi D, Viens P, Legros M, Oberling F, Philip T, Herve P, Plagne R, Dufour P, Bergerat JP, Guastalla JP, et al. Maraninchi D, et al. Bull Cancer. 1990;77(2):149-57. Bull Cancer. 1990. PMID: 2156587 French.
High dose melphalan and autologous marrow rescue in advanced epithelial ovarian carcinomas: a retrospective analysis of 35 patients treated in France.
Viens P, Maraninchi D, Legros M, Oberling F, Philip T, Herve P, Plagne R, Dufour P, Bergerat JP, Guastalla JP, et al. Viens P, et al. Bone Marrow Transplant. 1990 Apr;5(4):227-33. Bone Marrow Transplant. 1990. PMID: 2337735
Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation.
Blaise D, Olive D, Stoppa AM, Viens P, Pourreau C, Lopez M, Attal M, Jasmin C, Monges G, Mawas C, et al. Blaise D, et al. Blood. 1990 Sep 15;76(6):1092-7. Blood. 1990. PMID: 2400805
Increases in eosinophil and lymphocyte counts were significant (P less than .05). Stimulation of the immune system was intense and prolonged, manifested by increase numbers of CD3+, CD3+DR+, CD3+ CD25+ lymphocytes, and natural killer (NK) cells (all P less than .01) …
Increases in eosinophil and lymphocyte counts were significant (P less than .05). Stimulation of the immune system was intense and pr …
5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer.
Santini J, Milano G, Thyss A, Renee N, Viens P, Ayela P, Schneider M, Demard F. Santini J, et al. Br J Cancer. 1989 Feb;59(2):287-90. doi: 10.1038/bjc.1989.59. Br J Cancer. 1989. PMID: 2930694 Free PMC article.
There was a statistical difference in complete response rates between group 1 (31%) and group 2 (47%), (0.02 less than P less than 0.05) and a statistically significant reduction was observed in the incidence of toxic cycles (greater than grade 2, group 1 = 20% versus grou …
There was a statistical difference in complete response rates between group 1 (31%) and group 2 (47%), (0.02 less than P less than 0. …
p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results.
Jacquemier J, Molès JP, Penault-Llorca F, Adélaide J, Torrente M, Viens P, Birnbaum D, Theillet C. Jacquemier J, et al. Br J Cancer. 1994 May;69(5):846-52. doi: 10.1038/bjc.1994.164. Br J Cancer. 1994. PMID: 7514027 Free PMC article.

A statistically significant correlation was observed between p53 expression, regardless of the number of positive antibodies, and grade III disease (P < 0.0001), oestrogen (P < 0.0001) or progesterone receptor negativity (P = 0.0061), increased Ki 67 in

A statistically significant correlation was observed between p53 expression, regardless of the number of positive antibodies, and grade III …
419 results
Jump to page
Feedback